BC Cancer, part of the Provincial Health Services Authority
$100,000.00 CAD
≈ 16 months of average Canadian pay
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2020-2021
- Agreement period
- April 30, 2020 – January 14, 2021
- Reference
- nrc-cnrc:172-2020-2021-Q1-948910
Published purpose
This project will develop a lead candidate anti-CD22 CAR (Chimeric Antigen Receptor) comprising a camelid antibody derived anti-CD22 binding domain (developed by NRC) in the context of a CAR backbone and lentiviral vector system (developed by BC Cancer), suitable for inclusion in a CTA (Clinical Trial Application) submission to Health Canada
Community tags
Tags are applied by readers, not by this site. One tag per person per record.
Good value
Local impact
Needs context
Questionable
Success story
Wasteful
View official source record
Imported July 30, 2026 from open.canada.ca Grants & Contributions